Stayble Therapeutics (Sweden) Insiders
| STABL Stock | SEK 0.41 0.01 2.50% |
Stayble Therapeutics employs about 3 people. The company is managed by 4 executives with a total tenure of roughly 7 years, averaging almost 1.0 years of service per executive, having 0.75 employees per reported executive. Breaking down Stayble Therapeutics' management performance can provide insight into the firm performance.
| Anders Lehmann Insider Chief Officer |
| Mattias MSc Insider CoFounder Officer |
Stayble |
Stayble Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.4406) % which means that it has lost $0.4406 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.764) %, meaning that it generated substantial loss on money invested by shareholders. Stayble Therapeutics' management efficiency ratios could be used to measure how well Stayble Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Stayble Therapeutics Workforce Comparison
Stayble Therapeutics AB is currently regarded as top stock in number of employees category among its peers. The total workforce of Biotechnology industry is at this time estimated at about 61.0. Stayble Therapeutics holds roughly 3.0 in number of employees claiming about 5% of stocks in Biotechnology industry.
Stayble Therapeutics Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Stayble Therapeutics Price Series Summation is a cross summation of Stayble Therapeutics price series and its benchmark/peer.
Stayble Therapeutics Notable Stakeholders
A Stayble Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Stayble Therapeutics often face trade-offs trying to please all of them. Stayble Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Stayble Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Anders Lehmann | Chief Officer | Profile | |
| Mattias MSc | CoFounder Officer | Profile | |
| Andreas MSc | CoFounder CEO | Profile | |
| Thomas MSc | Chief Officer | Profile |
About Stayble Therapeutics Management Performance
The success or failure of an entity such as Stayble Therapeutics often depends on how effective the management is. Stayble Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Stayble management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Stayble management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Stayble Therapeutics AB develops injectable treatment for chronic low back pain triggered by disc degeneration. Stayble Therapeutics AB is based in Gothenburg, Sweden. Stayble Therapeutics is traded on Stockholm Stock Exchange in Sweden.
Please note, the imprecision that can be found in Stayble Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Stayble Therapeutics AB. Check Stayble Therapeutics' Beneish M Score to see the likelihood of Stayble Therapeutics' management manipulating its earnings.
Stayble Therapeutics Workforce Analysis
Traditionally, organizations such as Stayble Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Stayble Therapeutics within its industry.Stayble Therapeutics Manpower Efficiency
Return on Stayble Therapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 4M | |
| Net Loss Per Executive | 3M |
Additional Tools for Stayble Stock Analysis
When running Stayble Therapeutics' price analysis, check to measure Stayble Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Stayble Therapeutics is operating at the current time. Most of Stayble Therapeutics' value examination focuses on studying past and present price action to predict the probability of Stayble Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Stayble Therapeutics' price. Additionally, you may evaluate how the addition of Stayble Therapeutics to your portfolios can decrease your overall portfolio volatility.